Medscape

Fracture Healing Appears Unaffected by Denosumab

Denosumab (Prolia, Amgen, Inc) does not appear to delay fracture healing or cause other complications when given at or near the time of fracture in postmenopausal women with osteoporosis, according to ...
Healio

Cyclic teriparatide, denosumab administration benefits cortical BMD in osteoporosis

Please provide your email address to receive an email when new articles are posted on . Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily ...
MedPage Today

Calcium Levels Quickly Become Critical for Many Denosumab-Treated Women on Dialysis

Many women on dialysis quickly developed severe hypocalcemia after starting denosumab (Prolia) for osteoporosis, Medicare data showed. During the first 12 weeks of treatment, 41.1% of women on ...
Healio

Denosumab effective in transfusion-dependent thalassemia-induced osteoporosis

Please provide your email address to receive an email when new articles are posted on . A twice-yearly injection of denosumab improved spinal bone mineral density among individuals with osteoporosis ...
Australian Ageing Agenda

Residents at risk due to missed osteoporosis medication

AIHI research finds the recommended treatments are frequently missed or delayed in residential aged care, increasing the risk ...
manilatimes

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients living with osteoporosis and ...
Medscape

Denosumab Superior to Zoledronic Acid in Advanced Breast Cancer

November 10, 2010 — In advanced breast cancer patients who have bone metastases, the novel biologic denosumab was superior to zoledronic acid in preventing skeletal-related events (SREs) and renal ...
Yahoo Finance

Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®

JERSEY CITY, N.J., March 3, 2025 /PRNewswire/ -- Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO ® (CT-P41, denosumab-bmwo) and OSENVELT ® (CT-P41, ...
Business Insider

Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis

"Today's positive opinion by the CHMP is an important step for Prolia in helping patients suffering from bone loss associated with systemic glucocorticoid therapy," said Sean E. Harper, M.D., ...
ascopubs.org

Denosumab: Second Chapter in Controlling Bone Metastases or a New Book?

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study Abbreviation: FDA, US Food and Drug ...
ascopubs.org

Denosumab for Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors: Incremental Benefit, Debatable Value

Correcting for Discretionary Treatment Crossover in an Analysis of Survival in the Breast International Group BIG 1-98 Trial by Using the Inverse Probability of Censoring Weighted Method Bone ...